Live thread

Abivax stock plunges after negative clinical trial results

The stock of French biotech company Abivax has plummeted by over 30 percent after the firm disclosed safety concerns with its lead drug for ulcerative colitis. Cancer cases were observed in patients receiving higher doses.

This story is part of Kirla. Sign in to read the full coverage.

Sign in to read